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Abstract
Background: Prophylactic cotrimoxazole is recommended for infants born to HIV-infected mothers. However, cotrimoxazole
may increase the risk of severe anemia or neutropenia.
Methods: We compared the proportion of HIV-exposed uninfected (HIV-EU) infants experiencing incident severe anemia
(and separately, severe neutropenia) between a prospective cohort receiving prophylactic cotrimoxazole from 1 to 6
months vs. infants from two prior trials who did not receive cotrimoxazole. Infants were from rural and urban communities
in southern Botswana.
Results: A total of 1705 HIV-EU infants were included. Among these 645 (37.8%) were fed with iron-supplemented formula
from birth. Severe anemia developed in 87 (5.1%) infants, and severe neutropenia in 164 (9.6%) infants. In an analysis
stratified by infant feeding method, there were no significant differences in the risk of severe anemia by prophylactic
cotrimoxazole exposure–risk difference, 20.69% (95% confidence interval [CI] 22.1 to 0.76%). Findings were similar in
multivariable analysis, adjusted odds ratio (aOR) 0.35 (95% CI 0.07 to 1.65). There were also no significant differences
observed for severe neutropenia by cotrimoxazole exposure, risk difference 2.0% (95% CI 21.3 to 5.2%) and aOR 0.80 (95%
CI 0.33 to 1.93).
Conclusions: Severe anemia and severe neutropenia were infrequent among HIV-exposed uninfected infants receiving
cotrimoxazole from 1–6 months of age. Concerns regarding hematologic toxicity should not limit the use of prophylactic
cotrimoxazole in HIV-exposed uninfected infants.
ClinicalTrials.gov Registration Numbers: NCT01086878 (http://clinicaltrials.gov/show/NCT01086878), NCT00197587 (http://
clinicaltrials.gov/show/NCT00197587), and NCT00270296 (http://clinicaltrials.gov/show/NCT00270296).
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Introduction
The World Health Organization (WHO) recommends that all
infants born to HIV-infected mothers receive prophylactic
cotrimoxazole until they are known to be HIV-uninfected and
they are no longer at risk of acquiring HIV via breastfeeding. [1]
Due to challenges with timely infant HIV diagnosis, the period of
recommended cotrimoxazole use for the majority of the nearly two
million HIV-exposed infants born in sub-Saharan Africa annually
[2] exceeds 6 months for formula-fed infants and is greater than 12
months for a majority of breastfed infants. However, with
maternal highly active antiretroviral therapy (HAART), less than
2% of infants acquire HIV infection. [3–5] With improved access
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recommendation to provide empiric cotrimoxazole prophylaxis for
all HIV-exposed infants has been questioned. [7].
Maternal HAART has been associated with increased risk of
infant anemia[8–11] [12] and neutropenia. [13,14] We previously
found an association between exposure to maternal HAART and
severe infant anemia [12]. Post-natal prophylactic infant zidovu-
dine likely further increases this risk. [15] Cotrimoxazole also can
adversely affect hematopoiesis, [16,17] although virtually no data
are available for the effect in infants. [18] The combination of
HAART and cotrimoxazole appears to increase risk of hemato-
logic toxicity in sub-Saharan African adults. [19–21] Infants may
be more vulnerable to this effect, as hemoglobin concentration falls
following birth reaching a physiologic nadir between 1 and 2
months of life before recovering by 6 months. [22,23] Provision of
prolonged cotrimoxazole prophylaxis to young infants may
potentiate anemia and neutropenia in HAART-exposed infants.
An increased risk of severe hematologic complications could
alter the balance of risks and benefits of the WHO strategy of
cotrimoxazole for all HIV-exposed infants. Additionally, there is
interest in using cotrimoxazole prophylaxis to reduce excess
morbidity in HIV-exposed uninfected (HIV-EU) infants. We
therefore sought to prospectively compare the proportion of
infants with incident severe anemia and incident severe neutro-
penia from one to six months of age between HIV-exposed infants
receiving cotrimoxazole prophylaxis in a new cohort (CTX) and
infants not receiving cotrimoxazole prophylaxis in two prior
similar cohorts (CTX-unexposed).
Methods
Ethics Statement
All participating mothers provided written informed consent for
themselves and on behalf of their infants. The studies were
reviewed and approved by the Botswana Health Research
Development Committee and the Institutional Review Board of
the Harvard School of Public Health. The trial clinicaltrials.gov
registration numbers are NCT01086878, NCT00197587, and
NCT00270296. The protocol for this trial and supporting
CONSORT checklist are available as supporting information;
see Checklist S1 and Protocol S1.
Study Design
We performed a prospective, historically-controlled clinical trial
of prophylactic cotrimoxazole. We compared the frequency of
hematologic toxicity between HIV-EU infants in a new prospec-
tive cohort (CTX) that received cotrimoxazole prophylaxis, and
HIV-EU infants in two prior studies (Mashi and Mma Bana) that
did not receive cotrimoxazole prophylaxis (CTX-unexposed).
Infants were followed in the same communities and clinics, and
resided in non-malarial regions of Botswana.
To emulate current practice where infant HIV diagnosis may be
delayed until beyond 6 months, HIV-EU infants in the CTX
cohort were assigned to receive cotrimoxazole (Purbac suspension,
Aspen Pharmacare Limited, Johannesburg, South Africa) from 1
to 6 months of age, regardless of feeding method. Recommended
weight-based dosing of cotrimoxazole was used (,5 kg, 100 mg
sulfamethoxazole/20 mg trimethoprim once daily; $5 kg,
200 mg sulfamethoxazole/40 mg trimethoprim once daily).
[1,24] The frequencies of anemia and neutropenia in this cohort
were compared with frequencies of these outcomes among HIV-
EU infants in the CTX-unexposed cohort which did not provide
cotrimoxazole prophylaxis to uninfected infants (Figure 1).
Study Subjects
For the CTX cohort, we approached HIV-infected mothers
receiving antenatal HAART who delivered live-born infants
between February 2009 and April 2010. According to national
guidelines at the time of the study, [24] women with CD4 cell
count #250 cells/ mL or WHO clinical stage 3 or 4 were eligible
for HAART. Women were provided with feeding counseling, and
were eligible for the study whether they opted to breastfeed or
formula-feed. Infants born to consenting mothers were enrolled in
the CTX cohort when they returned to the study clinic at one
month of age. The Mashi and Mma Bana trials enrolled pregnant
women and their infants. The HIV-uninfected infants from these
trials were included in the CTX-unexposed cohort if they attended
the scheduled clinic visit at one month of age.
All infants were recommended to receive single-dose nevirapine
at birth and 4 weeks of zidovudine prophylaxis. Breastfeeding
infants in the Mashi trial were assigned to receive extended
zidovudine through 6 months. Breastfeeding mothers in all cohorts
were counseled to wean at 6 months. Replacement-fed infants in
all cohorts received iron-fortified formula free of charge through
the Botswana national program and mother received prenatal iron
supplementation. Immediate cord clamping was the standard
obstetrical practice during all three studies. Interviews with
midwives caring for subjects in all three cohorts indicate that
there has not been a change in maternal or infant supplements.
Details of maternal and infant interventions of the cohorts are
summarized in Table S1.
Adherence to cotrimoxazole was assessed through self-report
and pharmacy refill records. Infants were weighed at each visit to
confirm appropriate dosage. All women were taught by a nurse at
each visit about the appropriate dose to administer.
Laboratory Measurements
Infants had laboratory measurements at birth and at 1, 3, and 6
months (other than for Mashi formula-fed infants who were seen at
birth and at 1, 4, and 7 months). Peripheral blood for a full blood
count with differential was taken at each scheduled visit (no
measurement at birth in CTX cohort). Full blood counts were
performed using the Sysmex XE 2100 automated flow cytometry
analyzer (Sysmex Corporation, Kobe, Japan). Infant HIV testing
was performed at similar intervals by qualitative polymerase chain
reaction (PCR) DNA assay using the Amplicor HIV-1 test (Roche
Diagnostic Systems, New Jersey).
Endpoints and Exposures
The primary endpoint was the first episode of severe (grade 3 or
4) anemia (or first episode of grade 3 or 4 neutropenia in a separate
analysis). Grading was according to the Division of AIDS (DAIDS)
toxicity tables, 2004 revision, developed from normative ranges
from the United States and Europe and expert opinion. [25] To
reduce ascertainment bias, only severe anemia or neutropenia
detected at scheduled 3 and 6 month visits (4 and 7 month visits in
Mashi formula-fed group) were considered as endpoints. Infants
born to mothers taking HAART starting at least one day prior to
delivery were defined as HAART-exposed and infants that did not
initiate breastfeeding prior to hospital discharge were considered
as formula-fed. Infants that initiated breastfeeding, but subse-
quently stopped prior to 6 months of age were considered as
breastfed for purposes of analysis.
Analytic Methods
The study was originally designed to detect a clinically
significant increase (10 percent absolute increase) in the proportion
Cotrimoxazole and Hematologic Toxicity
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severe anemia between infants receiving versus not receiving
cotrimoxazole. However, with increasing governmental support
for replacement feeding of HIV-EU infants in Botswana, we were
unable to enroll sufficient numbers of HIV-EU breastfed infants
for this comparison. Consequently, we opened enrollment in the
CTX cohort to both breastfed and formula-fed HIV-EU infants.
Among formula-fed infants, the modified design had greater than
90 percent power to detect an absolute 5 percent increase (above
the observed 1 percent in the Mashi trial) in the proportion with
severe anemia.
Analyses were restricted to HIV-uninfected infants. Stratifying
by infant feeding method, we used an exact Cochran-Mantel-
Haenszel test to examine for significant differences in cumulative
incident cases of severe anemia and severe neutropenia by
cotrimoxazole group. The Breslow-Day test was used to guide
decision of pooling stratified odds ratios. Multiple logistic
regression was used subsequently to adjust for baseline differences
between the cotrimoxazole exposure groups. Cotrimoxazole
assignment, antenatal maternal HAART, and infant feeding
method were retained in the model. Backwards stepwise model
selection, retaining all factors significantly associated (P,0.05)
with the outcome, was used to determine the final multivariable
model. Statistical analyses were performed using SAS, version 9.2
(SAS Institute, Cary, NC). All tests were 2-tailed, P values of less
than 0.05 were considered statistically significant.
Results
Study Infants
There were 2156 live infants (257 CTX, 1899 CTX-unexposed)
including 23 sets of twins, born to 2133 HIV-infected women in
the study cohorts. A total of 93 infants had detected HIV infection
through 7 months of age and were excluded from analysis. Forty-
two infants who died prior to 1 month of age and 246 infants who
did not attend the 1 month visit were also excluded. A total of
1775 infants were included in the cohort. Seventy infants did not
have available hematology measurements at 3 or 6 months of age,
leaving 1705 analyzable infants (203 CTX, 1502 CTX-unex-
posed). One CTX infant did not initiate cotrimoxazole (Figure 2).
Maternal and infant characteristics are summarized in Table 1.
A total of 645 (37.8%) of infants formula-fed from birth, while
1060 (62.2%) breastfed from birth. Mothers of CTX infants had
higher incomes, more education, and higher prevalence of
antenatal HAART exposure compared with mothers of infants
not receiving cotrimoxazole (reflecting differences in study design
and eligibility criteria for participants in these studies). Perhaps as
a consequence of maternal HAART (which was more frequently
used in the CTX cohort than in the historical cohorts), [12,26,27]
CTX infants were more frequently premature and small for
gestational age, and had lower hemoglobin concentrations at 1
month than the infants not receiving cotrimoxazole.
Completeness of Hematology Data
Hematologic measurements were available at either 3 or 6
months for 96% of infants. Measurements at both of these visits
were available for 81%. There were not significant differences in
completeness of study measurements by exposure to cotrimoxazole
or maternal HAART, feeding method, or study cohort.
Adherence to Cotrimoxazole
Among infants initiating cotrimoxazole, 94% completed the
prophylaxis through 6 months as assessed through pharmacy
refills. Reasons for premature discontinuation in the 13 infants
were as follows: death (3 cases of gastroenteritis and 1 case of
possible sudden infant death syndrome), mild rash (1), mild
persistent diarrhea (1), mother opted to stop medication without
specifying reason (1), and did not return for medication refill (6).
Primary Outcomes
Severe anemia. Protocol-defined severe anemia (grade 3 or
4) developed in 2 CTX infants (1.0%) and in 85 CTX-unexposed
infants (5.7%). Nearly all infants with severe anemia (93%) were
breastfed. In an analysis stratified by infant feeding method, there
were no significant differences in the risk of severe anemia by
prophylactic cotrimoxazole exposure – odds ratio 0.57 (95%
confidence interval [CI] 0.12 to 2.77), exact Cochran-Mantel-
Haenszel P=0.75). The stratified estimates of the risk difference,
20.69% (95% CI -2.1 to 0.76%), indicate that a clinically
Figure 1. Schematic of infant exposures in study cohorts. ZDV, zidovudine; supp., supplementation; CTX, cotrimoxazole; HAART, highly-active
antiretroviral therapy; mo., month.
aHAART became available through a national program in October 2002, subsequently women in Mashi trial with
CD4#200 cells/ mL were offered HAART.
bInfants in the Mma Bana trial received 1 month of ZDV and breastfed infants in the Mashi trial received 6
months of ZDV.
cNineteen mothers (9.1%) in CTX cohort received non-ZDV-containing HAART.
doi:10.1371/journal.pone.0074171.g001
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exposure is unlikely (Table 2).
Findings in multivariable analyses were similar. In a model
adjusted for infant feeding method, antenatal maternal HAART,
and other significant baseline factors, the estimated adjusted odds
ratio (aOR) for severe anemia for CTX versus CTX-unexposed
was 0.35 (0.07 to 1.65), P=0.18. In this model, breastfeeding,
antenatal maternal HAART, male sex, and low maternal income
were all significantly associated with increased risk of severe
anemia (Table 3).
Recovery of hemoglobin concentrations from the expected
physiologic nadir between 6 and 8 weeks [23] did not appear to be
adversely affected by cotrimoxazole in formula-fed infants. Mean
hemoglobin for formula-fed infants receiving cotrimoxazole
measured at 6 months was slightly higher than that of infants
not receiving cotrimoxazole measured at 7 months, 11.9 versus
11.6 g/dL, respectively (P=0.010).
Severe neutropenia. Fourteen CTX infants (6.9%) and 150
CTX-unexposed infants (10.0%) developed severe neutropenia.
These events were also clustered among breastfed infants (133 of
154 severe neutropenia incidents occurred in breastfed infants).
Stratifying by infant feeding method, CTX was not significantly
associated with severe neutropenia, OR 1.41 (0.73 to 2.69),
P=0.29. The estimated confidence interval of the risk difference
(2.0%, 95% CI 21.3 to 5.2%) indicates that an absolute increase
in the proportion with severe neutropenia associated with
cotrimoxazole could be as large as 5%.
After adjustment for infant feeding method, antenatal maternal
HAART, and significant univariate factors, the adjusted odds ratio
for severe neutropenia for CTX versus CTX-unexposed was 0.80
(95% CI 0.33 to 1.93). Prolonged infant zidovudine exposure
(birth to 6 months in Mashi breastfed infants), village residence,
and measures of decreased socioeconomic measures were associ-
ated with increased risk of severe neutropenia in the multivariable
model.
Discussion
HIV-exposed uninfected (and predominantly formula-fed)
infants who received cotrimoxazole prophylaxis from 1 through
6 months of age experienced low frequency of severe anemia or
Figure 2. Enrollment and follow-up of study infants. HIV-uninfected infants in the Mashi and Mma Bana trials did not receive cotrimoxazole
prophylaxis and serve as a comparison group to the new cohort (CTX) that received cotrimoxazole prophylaxis. CTX, cotrimoxazole; 1 mo., one
month; FF, formula-fed; BF, breastfed.
doi:10.1371/journal.pone.0074171.g002
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Cotrimoxazole Prophylaxis (CTX)
No Cotrimoxazole Prophylaxis (CTX-
unexposed)
N=208 N=1567
n( % ) n( % )
Village residence 96 (46.2) 802 (51.2)
Maternal income
None 68 (32.7) 869 (56.1)
,$100 89 (42.8) 370 (23.9)
$$100 51 (24.5) 311 (20.1)
Maternal education
Primary or none 52 (25.0) 399 (25.7)
Secondary 140 (67.3) 1101 (71.0)
University 16 (7.7) 51 (3.3)
Maternal HAART 208 (100) 696 (44.4)
Maternal age (years), median (IQR) 31.7 (27.6, 35.0) 27.1 (23.4, 31.6)
Maternal CD4 (cells/ mL), median (IQR) 278 (202, 421) 362 (238, 503)
Male infant 105 (50.5) 808 (51.6)
Premature (,37 weeks) 45 (21.6) 202 (13.1)
Small for gestational age (,10 percentile) 47 (22.6) 177 (11.5)
Breastfed at discharge from maternity ward 17 (8.2) 1092 (69.7)
Infant hemoglobin (g/dL) at 1 month, median (IQR) 10.9 (9.9, 11.7) 11.1 (10.1, 12.2)
Infants with available hematology measurements 203 (97.6) 1502 (95.9)
Note: CTX, cotrimoxazole; IQR, interquartile range.
doi:10.1371/journal.pone.0074171.t001
Table 2. Severe infant anemia and severe neutropenia by prophylactic cotrimoxazole exposure.
Cotrimoxazole Prophylaxis No Cotrimoxazole Prophylaxis
(CTX) (CTX-unexposed)
N=203 N=1502
Severe Anemia
Breast-fed infants 0/17 (0%) 81/1043 (7.6%)
Formula-fed infants 2/186 (1.1%) 4/459 (0.9%)
Stratified pooled estimates
a
Odds ratio (95% CI) 0.57 (0.12 to 2.77), P=0.75
b
Risk difference (95% CI) 20.69% (22.1% to 0.76%)
Severe Neutropenia
Breast-fed infants 3/17 (17.7%) 130/1040 (12.5%)
Formula-fed infants 11/186 (5.9%) 20/458 (4.4%)
Stratified pooled estimates
a
Odds ratio (95% CI) 1.41 (0.73 to 2.69), P=0.29
b
Risk difference (95% CI) 2.0% (21.3% to 5.2%)
Analysis restricted to severe anemia or neutropenia (grade 3 or 4) detected at scheduled measurements at 3 and/or 6 months of age in HIV-exposed uninfected infants
in the CTX, Mashi, and Mma Bana cohorts.
Note: 95% CI, 95% confidence interval.
aMantel-Haenszel methodology.
bExact Cochran-Mantel-Haenszel.
doi:10.1371/journal.pone.0074171.t002
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respectively). Through comparison with historic and contempora-
neous infant cohorts, we found that that HIV-exposed uninfected
infants assigned to cotrimoxazole prophylaxis from 1 to 6 months
of age did not have significantly elevated risk for severe anemia or
neutropenia. Rather, maternal HAART and breastfeeding were
important factors associated with increased risk of severe
hematologic events.
Despite reluctance among clinicians to use cotrimoxazole in
patients at risk for anemia or neutropenia, the contribution of
prophylactic cotrimoxazole to these risks has not been previously
assessed in HIV-EU infants. HIV-exposed infants with anemia
appear to be at increased risk of death [28] and anemic children,
at least those with iron deficiency, [29] have poorer neurocognitive
outcomes. In a recent analysis of data from HPTN-046 conducted
in Uganda and Zimbabwe, nearly half of breastfed HIV-EU
infants exposed to prolonged cotrimoxazole developed severe
anemia or neutropenia by 6 months of age. [30] However, as all
infants were given cotrimoxazole in that study, the analysis was
unable assess whether cotrimoxazole contributed to the high
observed frequency of severe anemia or neutropenia.
It is reassuring therefore, that prolonged cotrimoxazole
prophylaxis was not significantly associated with increased risk of
severe anemia in the current study. While the design cannot
exclude the possibility of association, the magnitude of any
increased risk of severe anemia is unlikely to be of clinical
significance. The upper bound of the 95% confidence interval was
less than 1% absolute increase in frequency.
The clinical importance of asymptomatic neutropenia is
uncertain, particularly when normative ranges for African infants
may be significantly lower than ranges in the populations used in
the development of the DAIDS toxicity tables used in this and
other studies. [31–33] However, the findings of this study indicate
that an absolute increase in severe neutropenia related to
cotrimoxazole is likely to be at most 5%. In settings where either
continued breastfeeding or limited access to early infant HIV
diagnosis make the use of cotrimoxazole prophylaxis a consider-
ation, these negative findings are important to inform decisions
about the optimal period for prophylaxis.
This analysis was subject to several limitations. With the
majority of HIV-infected women in Botswana opting to formula-
feed their infants during the study period, we were unable to enroll
sufficient number of breastfeeding infants to fully assess whether
cotrimoxazole is associated with severe hematologic toxicity in
breastfed infants, who are at greater risk of anemia. While
harmonized data collection across the study cohorts facilitated
adjustment for potential confounding, some residual confounding
is likely given differences in the design of the parent studies and
possible temporal effects. Additionally, the observed low event
frequency in the CTX cohort makes multivariable adjustment and
calculation of confidence limits challenging. Despite these
limitations, the findings indicate that a clinically significant impact
of cotrimoxazole on severe hematologic toxicity is unlikely.
Table 3. Factors associated with severe anemia and severe neutropenia among HIV-exposed, uninfected infants.
Variable Severe Anemia Severe Neutropenia
Univariate Multivariable Univariate Multivariable
OR (95% CI) P-value
a aOR (95% CI) P-value
a OR (95% CI) P-value
a aOR (95% CI) P-value
a
Infant Cotrimoxazole, 1 to
6 months
b
1.24 (0.23–6.81) 0.81 0.35 (0.07–1.65) 0.18 1.38 (0.65–2.93) 0.41 0.80 (0.33–1.93) 0.62
Maternal Antenatal HAART 3.04 (1.86–4.97) ,0.001 2.46 (1.45–4.18) ,0.001 0.74 (0.54–1.02)
c 0.069 1.16 (0.53–2.52) 0.71
Breastfeeding 8.81 (3.8–20.3) ,0.001 4.84 (1.87–12.5) 0.001 2.85 (1.90–4.26)
c ,0.001 1.75 (0.77–3.96) 0.18
Male Sex 1.57 (1.01–2.45) 0.046 1.60 (1.02–2.52) 0.042 1.29 (0.93–1.86) 0.125 … …
Maternal personal income
,$100/month
5.45 (1.98–15.0) 0.001 5.30 (1.92–14.6) 0.001 0.94 (0.63–1.41) 0.776 … …
Assignment to Infant Zidovudine
1 to 6 months
1.02 (0.62–1.66) 0.94 … … 3.08 (2.22–4.28) ,0.001 2.82 (1.27–6.29) 0.011
Shared or No Toilet/Latrine 1.21 (0.67–2.17) 0.53 … … 0.56 (0.32–0.99) 0.045 0.54 (0.30–0.97) 0.034
Maternal Education, Secondary
or More
0.96 (0.58–1.58) 0.87 … … 0.61 (0.41–0.93) 0.020 0.63 (0.41–0.96) 0.0334
Village residence 0.86 (0.56–1.32) 0.49 … … 1.41 (1.02–1.95) 0.039 1.42 (1.02–1.99) 0.040
Maternal CD4+cell count (per
100 cells/ mL)
0.98 (0.88–1.09) 0.73 … … 1.02 (0.94–1.10) 0.64 … …
Maternal Age (per 10 years) 0.83 (0.56–1.24) 0.36 … … 0.90 (0.68–1.21) 0.496 … …
Small for Gestational Age
(,10th percentile)
1.39 (0.77–2.51) 0.28 … … 1.22 (0.77–1.94) 0.39 … …
Premature (,37 weeks gestation) 1.33 (0.75–2.25) 0.34 … … 1.03 (0.95–1.11) 0.54 … …
Prophylactic cotrimoxazole, maternal antenatal HAART use, and infant feeding method are included in the multivariable model, as are other significant factors from the
univariate analysis.
OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval; HAART, highly-active antiretroviral therapy.
aWald chi-square.
bTo avoid confounding effect of infant feeding method, univariate estimate for effect of cotrimoxazole is restricted to formula-fed infants. Multivariable analysis includes
both formula-fed and breastfed infants.
cA modest but significant interaction was noted between feeding method and maternal HAART with increased risk of severe neutropenia associated with breastfeeding
from a mother receiving HAART. However, in multivariable analysis this interaction was no longer significant.
doi:10.1371/journal.pone.0074171.t003
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exposed uninfected infants was not associated with an increased
risk of severe anemia or of severe neutropenia, even in the setting
of maternal HAART use. Concerns related to possible hemato-
logic toxicity should not limit the use of prophylactic cotrimox-
azole among HIV-exposed infants.
Supporting Information
Table S1 Comparison of Study Characteristics. Note:
CTX, cotrimoxazole; ULN, upper limit of normal; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; HAART,
highly-active antiretroviral therapy; ZDV, zidovudine; 3TC,
lamivudine; NVP, nevirapine; ABC, abacavir; LPV/r, ritonavir-
boosted lopinavir; PCR; polymerase chain reaction; SMX/TMP,
sulfamethoxazole/trimethoprim.
aMothers were required to be on
HAART at time of delivery, consequently had met national
criteria for HAART initiation previously (nadir CD4#250 cells/
mL or AIDS). But any current CD4 count was permitted.
bRecommended and most common antenatal regimen. Some
women received alternative regimens.
cDose of infant zidovudine
varied by infant age: birth to 1 month (4 mg/kg twice daily), 1 to 2
months (4 mg/kg three times daily), and 2 to 6 months (6 mg/kg
three times daily).
dIn August 2002 protocol was amended to
provide single-dose nevirapine to all infants.
eInfants randomized
to breastfeeding and long zidovudine group, had additional
measurements at 2, 3, 5, and 6 months.
(DOCX)
Checklist S1 CONSORT checklist.
(DOC)
Protocol S1 Study protocol ‘‘Safety of cotrimoxazole prophy-
laxis in HIV- and HAART-exposed infants in Botswana’’.
(PDF)
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